CORRECTING and REPLACING Sucampo Pharmaceuticals Provides Update on Anticipated Arbitration Decision
BETHESDA, Md.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions
The corrected release reads:
SUCAMPO PHARMACEUTICALS PROVIDES UPDATE ON ANTICIPATED ARBITRATION DECISION
Sucampo Pharmaceuticals, Inc. (SCMP) today announced that the International Court of Arbitration, International Chamber of Commerce (ICC) has notified the Company of a change in the anticipated date of the decision related to the Companys demand for arbitration under the applicable provisions of the Collaboration and License Agreement with Takeda Pharmaceutical Company Limited, or Takeda. The ICC has extended the date from June 29, 2012 to July 31, 2012.
Sucampo is eager to receive the ICCs decision as quickly as possible, and we continue our substantial planning in anticipation of a favorable award. Through these efforts, we look forward to increasing patient and healthcare provider access to AMITIZA® in the event of a favorable outcome.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc., an international pharmaceutical company is focused on the discovery, development and commercialization of proprietary drugs based on prostones. The therapeutic potential of prostones, which occur naturally in the human body as a result of enzymatic (15-PGDH) transformation of certain fatty acids, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' Chairman and Chief Executive Officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding Chief Executive Officer and currently Advisor, International Business Development, and a member of the Board of Directors. For more information, please visit www.sucampo.com.
Sucampo Forward-Looking Statements
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, future financial and operating results, and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of pharmaceutical industry regulation and health care legislation; Sucampo's ability to accurately predict future market conditions; dependence on the effectiveness of Sucampo's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the US and internationally and the exposure to litigation and/or regulatory actions.
No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Sucampo undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect Sucampo's business, particularly those mentioned in the risk factors and cautionary statements in Sucampo's Form 10-Q for the quarter ended May 10, 2012, which the Company incorporates by reference.
Sucampo Pharmaceuticals, Inc.
Silvia Taylor, 1-240-223-3718
Kate de Santis, 1-240-223-3834
Source: Sucampo Pharmaceuticals, Inc.Copyright Business Wire 2012